Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTH | P32929 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 9/20 | 0.34 |
| ▸ | THRA | P10827 | 6/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13684167 | 0.77 | — | — | |
| SCHEMBL24408065 | 0.76 | THRB (0.40) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL21749460 | 0.72 | — | — | |
| SCHEMBL24188741 | 0.72 | ALDH1A1 (0.40) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL31356397 | 0.71 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL24192726 | 0.69 | THRB (0.43) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL24193214 | 0.68 | HPGD (0.37) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL21769501 | 0.64 | CTH (0.37) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL20669613 | 0.64 | CTH (0.37) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL21533466 | 0.63 | CTH (0.39) | ALDH1A1CTHRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | ALDH1A1 3553/4885MAPT 2085/4885HPGD 3088/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | ALDH1A1 3553/4885MAPT 2085/4885HPGD 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.